Vivoryon Therapeutics Investor Relations Material

Vivoryon Therapeutics N.V., previously known as Probiodrug, is a Germany-based clinical-stage biopharmaceutical company. It specializes in the discovery and development of therapies for patients suffering from age-related diseases, with a primary focus on Alzheimer’s disease and cancer immune checkpoint inhibition. The company leverages its expertise in understanding post-translational modifications to develop small molecule medications that modulate the activity and stability of proteins altered in disease settings. The company is headquartered in Halle (Saale), Germany, and its shares are listed on the Euronext Amsterdam.